BUDZ Quote, Financials, Valuation and Earnings

Cencora has a net margin of -- compared to Weed's net margin of 0%. Weed's return on equity of -- beat Cencora's return on equity of 157.14%.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Cencora has an analysts' consensus of $266.34 which suggests that it could grow by 17.05%. Given that Cencora has higher upside potential than Weed, analysts believe Cencora is more attractive than Weed.

Weed has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison Cencora has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.467%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cencora offers a yield of 0.91% to investors and pays a quarterly dividend of $0.55 per share. Weed pays -- of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Weed quarterly revenues are --, which are smaller than Cencora quarterly revenues of $79.1B. Weed's net income of -$95.9K is lower than Cencora's net income of $3.4M. Notably, Weed's price-to-earnings ratio is 189.17x while Cencora's PE ratio is 30.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.16x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of -- compared to Weed's net margin of 0.26%. Weed's return on equity of -- beat McKesson's return on equity of --.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand McKesson has an analysts' consensus of $653.95 which suggests that it could grow by 12.92%. Given that McKesson has higher upside potential than Weed, analysts believe McKesson is more attractive than Weed.

Weed has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison McKesson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 51.023%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. McKesson offers a yield of 0.46% to investors and pays a quarterly dividend of $0.71 per share. Weed pays -- of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. McKesson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Weed quarterly revenues are --, which are smaller than McKesson quarterly revenues of $93.7B. Weed's net income of -$95.9K is lower than McKesson's net income of $241M. Notably, Weed's price-to-earnings ratio is 189.17x while McKesson's PE ratio is 29.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.23x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of -- compared to Weed's net margin of --. Weed's return on equity of -- beat Pineapple's return on equity of --.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Weed has higher upside potential than Pineapple, analysts believe Weed is more attractive than Pineapple.

Weed has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison Pineapple has a beta of 28.578, suggesting its more volatile than the S&P 500 by 2757.84%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend.

Weed quarterly revenues are --, which are smaller than Pineapple quarterly revenues of --. Weed's net income of -$95.9K is higher than Pineapple's net income of --. Notably, Weed's price-to-earnings ratio is 189.17x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 70.72x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of -- compared to Weed's net margin of -95.71%. Weed's return on equity of -- beat Zomedica's return on equity of -27.17%.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 108.33%. Given that Zomedica has higher upside potential than Weed, analysts believe Zomedica is more attractive than Weed.

Weed has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison Zomedica has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.385%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend.

Weed quarterly revenues are --, which are smaller than Zomedica quarterly revenues of $7M. Weed's net income of -$95.9K is higher than Zomedica's net income of -$6.7M. Notably, Weed's price-to-earnings ratio is 189.17x while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 4.40x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.